Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma

被引:9
|
作者
Rade, Michael [1 ]
Grieb, Nora [2 ,3 ]
Weiss, Ronald [1 ,4 ]
Sia, Jaren [5 ]
Fischer, Luise [2 ]
Born, Patrick [2 ]
Boldt, Andreas [4 ]
Fricke, Stephan [4 ]
Franz, Paul [4 ]
Scolnick, Jonathan [5 ]
Venkatraman, Lakshmi [5 ]
Xu, Stacy [5 ]
Kloetzer, Christina [2 ]
Heyn, Simone [2 ]
Kubasch, Anne Sophie [2 ]
Baber, Ronny [6 ,7 ]
Wang, Song Yau [2 ]
Bach, Enrica [2 ]
Hoffmann, Sandra [2 ]
Ussmann, Jule [2 ]
Schetschorke, Birthe [2 ]
Hell, Saskia [2 ]
Schwind, Sebastian [2 ]
Metzeler, Klaus H. [2 ]
Herling, Marco [2 ]
Jentzsch, Madlen [2 ]
Franke, Georg-Nikolaus [2 ]
Sack, Ulrich [4 ]
Koehl, Ulrike [1 ,4 ]
Platzbecker, Uwe [2 ]
Reiche, Kristin [1 ,4 ,8 ]
Vucinic, Vladan [2 ]
Merz, Maximilian [2 ]
机构
[1] Fraunhofer Inst Cell Therapy & Immunol IZI, Leipzig, Germany
[2] Univ Hosp Leipzig, Dept Hematol Cellular Therapy & Hemostaseol, Leipzig, Germany
[3] Univ Hosp Leipzig, Innovat Ctr Comp Assisted Surg, Leipzig, Germany
[4] Univ Hosp Leipzig, Inst Clin Immunol, Leipzig, Germany
[5] Singleron Biotechnol, Cologne, Germany
[6] Univ Hosp Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, Leipzig, Germany
[7] Univ Leipzig, Leipzig Med Biobank, Leipzig, Germany
[8] Ctr Scalable Data Analyt & Artificial Intelligence, Leipzig, Germany
关键词
THERAPY;
D O I
10.1038/s43018-024-00763-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Markers that predict response and resistance to chimeric antigen receptor (CAR) T cells in relapsed/refractory multiple myeloma are currently missing. We subjected mononuclear cells isolated from peripheral blood and bone marrow before and after the application of approved B cell maturation antigen-directed CAR T cells to single-cell multiomic analyses to identify markers associated with resistance and early relapse. Differences between responders and nonresponders were identified at the time of leukapheresis. Nonresponders showed an immunosuppressive microenvironment characterized by increased numbers of monocytes expressing the immune checkpoint molecule CD39 and suppressed CD8+ T cell and natural killer cell function. Analysis of CAR T cells showed cytotoxic and exhausted phenotypes in hyperexpanded clones compared to low/intermediate expanded clones. We identified potential immunotherapy targets on CAR T cells, like PD1, to improve their functionality and durability. Our work provides evidence that an immunosuppressive microenvironment causes resistance to CAR T cell therapies in multiple myeloma. Merz and colleagues perform single-cell multiomic analysis of mononuclear cells isolated from individuals receiving BCMA-directed CAR T cell therapy for myeloma and show that nonresponders are characterized by an immune-suppressive microenvironment.
引用
收藏
页码:1318 / 1333
页数:29
相关论文
共 50 条
  • [31] Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
    Larson, Rebecca C.
    Kann, Michael C.
    Graham, Charlotte
    Mount, Christopher W.
    Castano, Ana P.
    Lee, Won-Ho
    Bouffard, Amanda A.
    Takei, Hana N.
    Almazan, Antonio J.
    Scarfo, Irene
    Berger, Trisha R.
    Schmidts, Andrea
    Frigault, Matthew J.
    Gallagher, Kathleen M. E.
    Maus, Marcela V.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [32] Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies
    Angelos, Mathew G.
    Patel, Ruchi P.
    Ruella, Marco
    Barta, Stefan K.
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (02): : 171 - 186
  • [33] Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells
    Zhang, Wenqun
    Yang, Jing
    Zhou, Chunju
    Hu, Bo
    Jin, Ling
    Deng, Biping
    Liu, Yang
    Wang, Shan
    Chang, Alex H.
    Du, Juan
    Gao, Zifen
    Zhang, Yonghong
    BLOOD, 2020, 135 (26) : 2425 - 2427
  • [34] Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas
    Muhsen, Ibrahim N.
    Hill, LaQuisa C.
    Ramos, Carlos A.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (06) : 1107 - 1124
  • [35] Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma
    Yuti, Pornpimon
    Sawasdee, Nunghathai
    Natungnuy, Krissada
    Rujirachaivej, Punchita
    Luangwattananun, Piriya
    Sujjitjoon, Jatuporn
    Yenchitsomanus, Pathai
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 168
  • [36] Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update
    Lakshman, Arjun
    Kumar, Shaji K.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (01) : 99 - 118
  • [37] Switchable chimeric antigen receptor T cells: a novel universal chimeric antigen receptor platform for a safe control of T-cell activation
    Arcangeli, Silvia
    Magnani, Chiara F.
    Tettamanti, Sarah
    Biagi, Ettore
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S174 - S177
  • [38] Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
    Li, Chenggong
    Xu, Jia
    Luo, Wenjing
    Liao, Danying
    Xie, Wei
    Wei, Qiuzhe
    Zhang, Yinqiang
    Wang, Xindi
    Wu, Zhuolin
    Kang, Yun
    Zheng, Jin'e
    Xiong, Wei
    Deng, Jun
    Hu, Yu
    Mei, Heng
    LEUKEMIA, 2024, 38 (01) : 149 - 159
  • [39] sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
    Seipel, Katja
    Porret, Naomi
    Wiedemann, Gertrud
    Jeker, Barbara
    Bacher, Vera Ulrike
    Pabst, Thomas
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2022, 44 (04) : 1463 - 1471
  • [40] Absolute Lymphocyte Count Prior to Lymphodepletion Impacts Outcomes in Multiple Myeloma Patients Treated with Chimeric Antigen Receptor T Cells
    Liu, Yang
    Chen, Wei
    Yu, Mingxiao
    Li, Hujun
    Cheng, Hai
    Cao, Jiang
    Yan, Zhiling
    Shi, Ming
    Zhu, Feng
    Sun, Haiying
    Sang, Wei
    Li, Depeng
    Wu, Qingyun
    Chen, Chong
    Zheng, Junnian
    Xu, Kailin
    Li, Zhenyu
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (02): : 118.e1 - 118.e5